What Happens To AbbVie Stock If SKYRIZI Slows Down?

AbbVie (ABBV) is trading within about one percent of its 52-week high after gaining roughly 24% over the past year, well ahead of the S&P 500. That price rests on two drugs, SKYRIZI above all, growing faster than 20% year over year while the company's older medicines shrink.

The biggest risk to the stock makes no noise. It is the chance that this engine slows while the price assumes it cannot.